{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:27:23Z","timestamp":1791570443473,"version":"4.3.4"},"reference-count":181,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,3]]},"DOI":"10.1093\/bjs\/znad266","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T20:18:41Z","timestamp":1706041121000},"source":"Crossref","is-referenced-by-count":28,"title":["Surgery for advanced adrenal malignant disease: recommendations based on European Society of Endocrine Surgeons consensus meeting"],"prefix":"10.1093","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6153-1970","authenticated-orcid":false,"given":"Radu","family":"Mihai","sequence":"first","affiliation":[{"name":"Churchill Cancer Centre, Oxford University Hospital NHS Foundation Trust , Oxford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7303-9657","authenticated-orcid":false,"given":"Carmela","family":"De Crea","sequence":"additional","affiliation":[{"name":"Centro di Ricerca in Chirurgia delle Ghiandole Endocrine e dell\u2019Obesit\u00e0, Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"},{"name":"Endocrine Surgery Unit, Hospital Fatebenefratelli Isola Tiberina\u2014Gemelli Isola , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Guerin","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Surgery, Aix-Marseille University, H\u00f4pital de La Conception , Marseille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8543-9300","authenticated-orcid":false,"given":"Francesca","family":"Torresan","sequence":"additional","affiliation":[{"name":"Endocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua , Padua , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1617-3953","authenticated-orcid":false,"given":"Orhan","family":"Agcaoglu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Koc University School of Medicine , Istanbul , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7372-8591","authenticated-orcid":false,"given":"Razvan","family":"Simescu","sequence":"additional","affiliation":[{"name":"Department of General and Endocrine Surgery, Medlife-Humanitas Hospital , Cluj-Napoca , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5441-8563","authenticated-orcid":false,"given":"Martin K","family":"Walz","sequence":"additional","affiliation":[{"name":"Department of Surgery and Minimally Invasive Surgery, Kliniken Essen-Mitte , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"2024012320182548100_znad266-B1","doi-asserted-by":"crossref","first-page":"bvab180","DOI":"10.1210\/jendso\/bvab180","article-title":"Adrenal incidentaloma: prevalence and referral patterns from routine practice in a large UK university teaching hospital","volume":"6","author":"Hanna","year":"2022","journal-title":"J Endocr Soc"},{"key":"2024012320182548100_znad266-B2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00423-011-0893-5","article-title":"Positional statement of the European Society of Endocrine Surgeons (ESES) on malignant adrenal tumors","volume":"397","author":"Henry","year":"2012","journal-title":"Langenbecks Arch Surg"},{"key":"2024012320182548100_znad266-B3","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/bjs.10414","article-title":"European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma","volume":"104","author":"Gaujoux","year":"2017","journal-title":"Br J Surg"},{"key":"2024012320182548100_znad266-B5","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American Neuroendocrine Tumor Society Consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"key":"2024012320182548100_znad266-B8","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"key":"2024012320182548100_znad266-B9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Taieb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024012320182548100_znad266-B10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2024012320182548100_znad266-B11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2213-8587(20)30218-7","article-title":"Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study","volume":"8","author":"Bancos","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024012320182548100_znad266-B12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.surg.2022.07.029","article-title":"Differentiating between adrenocortical carcinoma and lipid-poor cortical adenoma: a novel cross-sectional imaging-based score","volume":"173","author":"Yalon","year":"2023","journal-title":"Surgery"},{"key":"2024012320182548100_znad266-B13","doi-asserted-by":"crossref","first-page":"101408","DOI":"10.1016\/j.beem.2020.101408","article-title":"Surgery for adrenocortical carcinoma: when and how?","volume":"34","author":"Sinclair","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4158\/EP-2018-0616","article-title":"Large adrenal incidentalomas require a dedicated diagnostic procedure","volume":"25","author":"Amodru","year":"2019","journal-title":"Endocr Pract"},{"key":"2024012320182548100_znad266-B15","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1210\/jc.2017-00254","article-title":"Performance of 18F-FDG PET\/CT in the characterization of adrenal masses in noncancer patients: a prospective study","volume":"102","author":"Guerin","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B16","doi-asserted-by":"crossref","first-page":"20170520","DOI":"10.1259\/bjr.20170520","article-title":"Diagnostic accuracy of 18F-FDG PET or PET\/CT for the characterization of adrenal masses: a systematic review and meta-analysis","volume":"91","author":"Kim","year":"2018","journal-title":"Br J Radiol"},{"key":"2024012320182548100_znad266-B17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00259-002-1025-9","article-title":"11C-metomidate PET imaging of adrenocortical cancer","volume":"30","author":"Khan","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024012320182548100_znad266-B18","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/jso.26639","article-title":"Adrenal biopsy, as a diagnostic method, is associated with decreased overall survival in patients with T1\/T2 adrenocortical carcinoma: a propensity score-matched analysis","volume":"124","author":"Naffouje","year":"2021","journal-title":"J Surg Oncol"},{"key":"2024012320182548100_znad266-B19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1530\/EJE-21-0510","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B20","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.surg.2014.08.018","article-title":"A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I\/II disease","volume":"156","author":"Asare","year":"2014","journal-title":"Surgery"},{"key":"2024012320182548100_znad266-B21","doi-asserted-by":"crossref","first-page":"1029155","DOI":"10.3389\/fgene.2022.1029155","article-title":"The prognosis difference between elderly and younger patients with adrenocortical carcinoma","volume":"13","author":"He","year":"2023","journal-title":"Front Genet"},{"key":"2024012320182548100_znad266-B22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-14-0913","article-title":"Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole","volume":"172","author":"Corcuff","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B23","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome","volume":"96","author":"Kamenicky","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0274","article-title":"Etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: a review","volume":"167","author":"Preda","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B25","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bjs.9743","article-title":"Diagnosis, treatment and outcome of adrenocortical cancer","volume":"102","author":"Mihai","year":"2015","journal-title":"Br J Surg"},{"key":"2024012320182548100_znad266-B26","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1245\/s10434-022-12711-w","article-title":"Open versus laparoscopic surgery in the management of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"30","author":"Nakanishi","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"2024012320182548100_znad266-B27","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1245\/s10434-020-08454-1","article-title":"Minimally invasive versus open adrenalectomy in patients with adrenocortical carcinoma: a meta-analysis","volume":"27","author":"Hu","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2024012320182548100_znad266-B28","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1245\/s10434-015-4900-x","article-title":"Open versus laparoscopic adrenalectomy for adrenocortical carcinoma: a meta-analysis of surgical and oncological outcomes","volume":"23","author":"Autorino","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2024012320182548100_znad266-B29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.euf.2015.12.001","article-title":"Surgical management of adrenocortical carcinoma: impact of laparoscopic approach, lymphadenectomy, and surgical volume on outcomes\u2014a systematic review and meta-analysis of the current literature","volume":"1","author":"Langenhuijsen","year":"2016","journal-title":"Eur Urol Focus"},{"key":"2024012320182548100_znad266-B30","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.3390\/jcm11195754","article-title":"Surgical management of adrenocortical carcinoma: a literature review","volume":"11","author":"Rossi","year":"2022","journal-title":"J Clin Med"},{"key":"2024012320182548100_znad266-B31","doi-asserted-by":"crossref","first-page":"455.e19","DOI":"10.1016\/j.urolonc.2022.05.021","article-title":"Association of tumor size and surgical approach with oncological outcomes and overall survival in patients with adrenocortical carcinoma","volume":"40","author":"Ginsburg","year":"2022","journal-title":"Urol Oncol"},{"key":"2024012320182548100_znad266-B32","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.amjsurg.2020.02.043","article-title":"Risk factors associated with positive resection margins in patients with adrenocortical carcinoma","volume":"220","author":"Skertich","year":"2020","journal-title":"Am J Surg"},{"key":"2024012320182548100_znad266-B33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.eururo.2010.06.024","article-title":"Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients","volume":"58","author":"Brix","year":"2010","journal-title":"Eur Urol"},{"key":"2024012320182548100_znad266-B34","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s00464-013-3034-0","article-title":"Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?","volume":"27","author":"Cooper","year":"2013","journal-title":"Surg Endosc"},{"key":"2024012320182548100_znad266-B35","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3109\/0284186X.2013.765065","article-title":"Laparoscopic versus open surgery in stage I\u2013III adrenocortical carcinoma\u2014a retrospective comparison of 32 patients","volume":"52","author":"Fossa","year":"2013","journal-title":"Acta Oncol"},{"key":"2024012320182548100_znad266-B36","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1007\/s00268-010-0532-2","article-title":"Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma","volume":"34","author":"Miller","year":"2010","journal-title":"World J Surg"},{"key":"2024012320182548100_znad266-B37","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1245\/s10434-012-2760-1","article-title":"Comparative outcomes of laparoscopic and open adrenalectomy for adrenocortical carcinoma: single, high-volume center experience","volume":"20","author":"Mir","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"2024012320182548100_znad266-B38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00268-017-4290-2","article-title":"Minimally invasive adrenalectomy for adrenocortical carcinoma: five-year trends and predictors of conversion","volume":"42","author":"Calcatera","year":"2018","journal-title":"World J Surg"},{"key":"2024012320182548100_znad266-B39","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1007\/s00464-021-08827-x","article-title":"A comparison of robotic and laparoscopic minimally invasive adrenalectomy for adrenal malignancies","volume":"36","author":"Hue","year":"2022","journal-title":"Surg Endosc"},{"key":"2024012320182548100_znad266-B40","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1245\/s10434-020-08824-9","article-title":"Implications of conversion during attempted minimally invasive adrenalectomy for adrenocortical carcinoma","volume":"28","author":"Delozier","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2024012320182548100_znad266-B41","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/biomedicines10061310","article-title":"From SGAP-model to SGAP-score: a simplified predictive tool for post-surgical recurrence of pheochromocytoma","volume":"10","author":"Parasiliti-Caprino","year":"2022","journal-title":"Biomedicines"},{"key":"2024012320182548100_znad266-B42","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00423-019-01827-5","article-title":"Volume\u2013outcome correlation in adrenal surgery\u2014an ESES consensus statement","volume":"404","author":"Mihai","year":"2019","journal-title":"Langenbecks Arch Surg"},{"key":"2024012320182548100_znad266-B43","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/bjs\/znab142","article-title":"Volume\u2013outcome relationship for adrenalectomy: analysis of an administrative dataset for the Getting It Right First Time Programme","volume":"108","author":"Gray","year":"2021","journal-title":"Br J Surg"},{"key":"2024012320182548100_znad266-B44","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40618-015-0422-4","article-title":"Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?","volume":"39","author":"Porpiglia","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"2024012320182548100_znad266-B45","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.21037\/gs.2019.06.03","article-title":"Surgical management of adrenal tumours extending into the right atrium","volume":"8","author":"Greco","year":"2019","journal-title":"Gland Surg"},{"key":"2024012320182548100_znad266-B46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00423-011-0876-6","article-title":"Outcome of operation in patients with adrenocortical cancer invading the inferior vena cava\u2014a European Society of Endocrine Surgeons (ESES) survey","volume":"397","author":"Mihai","year":"2012","journal-title":"Langenbecks Arch Surg"},{"key":"2024012320182548100_znad266-B47","doi-asserted-by":"crossref","first-page":"101544","DOI":"10.1016\/j.suronc.2021.101544","article-title":"Adrenal tumors of different types with or without tumor thrombus invading the inferior vena cava: an evaluation of 33 cases","volume":"37","author":"Ciancio","year":"2021","journal-title":"Surg Oncol"},{"key":"2024012320182548100_znad266-B48","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/jso.26138","article-title":"Critical analysis of lymph node examination in patients undergoing curative-intent resection for adrenocortical carcinoma","volume":"122","author":"Deschner","year":"2020","journal-title":"J Surg Oncol"},{"key":"2024012320182548100_znad266-B49","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1245\/s10434-021-11051-5","article-title":"Adrenocortical carcinoma: the value of lymphadenectomy","volume":"29","author":"Tseng","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2024012320182548100_znad266-B50","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00268-014-2484-4","article-title":"Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy","volume":"38","author":"Bednarski","year":"2014","journal-title":"World J Surg"},{"key":"2024012320182548100_znad266-B51","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/iju5.12458","article-title":"Long-term survival of a patient with refractory advanced adrenocortical carcinoma after combination chemotherapy with paclitaxel and carboplatin plus mitotane","volume":"5","author":"Kobayakawa","year":"2022","journal-title":"IJU Case Rep"},{"key":"2024012320182548100_znad266-B52","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211038409","article-title":"Management of adrenocortical carcinoma: are we making progress?","volume":"13","author":"Kiesewetter","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"2024012320182548100_znad266-B53","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the Brescia experience","volume":"12","author":"Lagana","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2024012320182548100_znad266-B54","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.surg.2019.05.024","article-title":"Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: analysis from the US adrenocortical carcinoma database","volume":"167","author":"Prendergast","year":"2020","journal-title":"Surgery"},{"key":"2024012320182548100_znad266-B55","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.2147\/OTT.S147352","article-title":"Primary site surgery for metastatic adrenocortical carcinoma improves survival outcomes: an analysis of a population-based database","volume":"10","author":"Wang","year":"2017","journal-title":"Onco Targets Ther"},{"key":"2024012320182548100_znad266-B56","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1210\/clinem\/dgab865","article-title":"Cytoreductive surgery of the primary tumor in metastatic adrenocortical carcinoma: impact on patients\u2019 survival","volume":"107","author":"Srougi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B57","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.3390\/curroncol28060370","article-title":"Tumor doubling time using CT volumetric segmentation in metastatic adrenocortical carcinoma","volume":"28","author":"Fuller","year":"2021","journal-title":"Curr Oncol"},{"key":"2024012320182548100_znad266-B58","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.surg.2020.10.041","article-title":"Operative intervention for recurrence of adrenocortical carcinoma: a single-center experience","volume":"169","author":"Zhang","year":"2021","journal-title":"Surgery"},{"key":"2024012320182548100_znad266-B59","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.surg.2016.08.058","article-title":"Surgery for recurrent adrenocortical carcinoma: a multicenter retrospective study","volume":"161","author":"Simon","year":"2017","journal-title":"Surgery"},{"key":"2024012320182548100_znad266-B60","doi-asserted-by":"crossref","first-page":"781406","DOI":"10.3389\/fsurg.2022.781406","article-title":"Reoperation for recurrent adrenocortical carcinoma: a systematic review and pooled analysis of population-based studies","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Surg"},{"key":"2024012320182548100_znad266-B61","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/ejendo\/lvad002","article-title":"The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients","volume":"188","author":"Calabrese","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B62","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jamcollsurg.2016.08.568","article-title":"Clinical score predicting long-term survival after repeat resection for recurrent adrenocortical carcinoma","volume":"223","author":"Tran","year":"2016","journal-title":"J Am Coll Surg"},{"key":"2024012320182548100_znad266-B63","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1007\/s00330-020-07019-w","article-title":"Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation","volume":"30","author":"Veltri","year":"2020","journal-title":"Eur Radiol"},{"key":"2024012320182548100_znad266-B64","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1186\/s12885-017-3506-z","article-title":"Outcome after resection of adrenocortical carcinoma liver metastases: a retrospective study","volume":"17","author":"Baur","year":"2017","journal-title":"BMC Cancer"},{"key":"2024012320182548100_znad266-B65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.hpb.2019.07.002","article-title":"Disease-free interval and tumor functional status can be used to select patients for resection\/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study","volume":"22","author":"Ayabe","year":"2020","journal-title":"HPB (Oxford)"},{"key":"2024012320182548100_znad266-B66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12672-019-00367-0","article-title":"Metastatic adrenocortical carcinoma: a single institutional experience","volume":"10","author":"Owen","year":"2019","journal-title":"Horm Cancer"},{"key":"2024012320182548100_znad266-B67","doi-asserted-by":"crossref","first-page":"20","DOI":"10.5306\/wjco.v9.i1.20","article-title":"Yttrium-90 microsphere selective internal radiation therapy for liver metastases following systemic chemotherapy and surgical resection for metastatic adrenocortical carcinoma","volume":"9","author":"Makary","year":"2018","journal-title":"World J Clin Oncol"},{"key":"2024012320182548100_znad266-B68","doi-asserted-by":"crossref","first-page":"bvac091","DOI":"10.1210\/jendso\/bvac091","article-title":"Yttrium-90 selective internal radiation therapy plus cryoablation for recurrent adrenocortical carcinoma with liver metastases","volume":"6","author":"Lin","year":"2022","journal-title":"J Endocr Soc"},{"key":"2024012320182548100_znad266-B69","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13550-021-00755-0","article-title":"Yttrium-90 radioembolization of isolated hepatic adrenocortical carcinoma metastases with negative surgical pathology","volume":"11","author":"Lu","year":"2021","journal-title":"EJNMMI Res"},{"key":"2024012320182548100_znad266-B70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/EJE-19-0026","article-title":"Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study","volume":"180","author":"Berruti","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B71","doi-asserted-by":"crossref","first-page":"zraa036","DOI":"10.1093\/bjsopen\/zraa036","article-title":"Comparative performances of nomograms and conditional survival after resection of adrenocortical cancer","volume":"5","author":"de Jong","year":"2021","journal-title":"BJS Open"},{"key":"2024012320182548100_znad266-B72","doi-asserted-by":"crossref","first-page":"e220114","DOI":"10.1530\/EC-22-0114","article-title":"S-GRAS score performs better than a model from SEER for patients with adrenocortical carcinoma","volume":"11","author":"Lin","year":"2022","journal-title":"Endocr Connect"},{"key":"2024012320182548100_znad266-B73","doi-asserted-by":"crossref","first-page":"e220372","DOI":"10.1530\/ERC-22-0372","article-title":"Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma","volume":"30","author":"Mangone","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2024012320182548100_znad266-B74","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00268-020-05868-6","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as possible prognostic markers for patients undergoing resection of adrenocortical carcinoma","volume":"45","author":"de Jong","year":"2021","journal-title":"World J Surg"},{"key":"2024012320182548100_znad266-B75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrendo.2013.272","article-title":"The \u2018omics\u2019 of adrenocortical tumours for personalized medicine","volume":"10","author":"Assie","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"2024012320182548100_znad266-B76","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1210\/endrev\/bnac012","article-title":"Update on biology and genomics of adrenocortical carcinomas: rationale for emerging therapies","volume":"43","author":"Lerario","year":"2022","journal-title":"Endocr Rev"},{"key":"2024012320182548100_znad266-B77","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","article-title":"Overview of the 2022 WHO classification of adrenal cortical tumors","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"2024012320182548100_znad266-B78","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.surg.2018.04.044","article-title":"Adrenocortical oncocytic neoplasm: a systematic review","volume":"164","author":"Kanitra","year":"2018","journal-title":"Surgery"},{"key":"2024012320182548100_znad266-B79","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41379-018-0077-8","article-title":"Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation","volume":"31","author":"Renaudin","year":"2018","journal-title":"Mod Pathol"},{"key":"2024012320182548100_znad266-B80","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.3390\/cancers14163904","article-title":"The overall survival and progression-free survival in patients with advanced adrenocortical cancer is increased after the multidisciplinary team evaluation","volume":"14","author":"Tizianel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024012320182548100_znad266-B81","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"2024012320182548100_znad266-B82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2022.03.032","article-title":"Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma","volume":"169","author":"Pamporaki","year":"2022","journal-title":"Eur J Cancer"},{"key":"2024012320182548100_znad266-B83","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.surg.2018.05.001","article-title":"A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score","volume":"164","author":"Cho","year":"2018","journal-title":"Surgery"},{"key":"2024012320182548100_znad266-B84","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B85","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41440-019-0339-y","article-title":"Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy","volume":"43","author":"Parasiliti-Caprino","year":"2020","journal-title":"Hypertens Res"},{"key":"2024012320182548100_znad266-B86","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-prono study): a European Network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B87","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.suronc.2017.11.003","article-title":"Factors related to improved clinical outcomes associated with adrenalectomy for metachronous adrenal metastases from solid primary carcinomas","volume":"27","author":"Cho","year":"2018","journal-title":"Surg Oncol"},{"key":"2024012320182548100_znad266-B88","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1515\/cclm-2020-0904","article-title":"Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma","volume":"59","author":"Eisenhofer","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"2024012320182548100_znad266-B89","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin Chem"},{"key":"2024012320182548100_znad266-B90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/EJE-17-0077","article-title":"Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma","volume":"177","author":"Rao","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B91","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype\u2013phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2024012320182548100_znad266-B92","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr Rev"},{"key":"2024012320182548100_znad266-B93","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Garcia-Carbonero","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"2024012320182548100_znad266-B94","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B95","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s00268-022-06862-w","article-title":"Genotype\u2013phenotype correlations and clinical outcomes in 155 cases of pheochromocytoma and paraganglioma","volume":"47","author":"Wang","year":"2023","journal-title":"World J Surg"},{"key":"2024012320182548100_znad266-B96","first-page":"1239","article-title":"TNM staging and overall survival in patients with pheochromocytoma and sympathetic paraganglioma","volume":"107","author":"Jimenez","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B97","doi-asserted-by":"crossref","first-page":"e220167","DOI":"10.1530\/JME-22-0167","article-title":"Genetic bases of pheochromocytoma and paraganglioma","volume":"70","author":"Cascon","year":"2023","journal-title":"J Mol Endocrinol"},{"key":"2024012320182548100_znad266-B98","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/jmedgenet-2017-105127","article-title":"Tumour risks and genotype\u2013phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD","volume":"55","author":"Andrews","year":"2018","journal-title":"J Med Genet"},{"key":"2024012320182548100_znad266-B99","doi-asserted-by":"crossref","first-page":"e1917","DOI":"10.1210\/clinem\/dgac014","article-title":"Universal germline panel testing for individuals with pheochromocytoma and paraganglioma produces high diagnostic yield","volume":"107","author":"Horton","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B100","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat Commun"},{"key":"2024012320182548100_znad266-B101","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"2024012320182548100_znad266-B102","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3390\/cancers11020225","article-title":"The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas\u2014a meta-analysis and systematic review of the literature","volume":"11","author":"Stenman","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2024012320182548100_znad266-B103","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2024012320182548100_znad266-B104","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/jcm7090242","article-title":"Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine","volume":"7","author":"Kimura","year":"2018","journal-title":"J Clin Med"},{"key":"2024012320182548100_znad266-B105","doi-asserted-by":"crossref","first-page":"e4661","DOI":"10.1210\/clinem\/dgaa608","article-title":"Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems","volume":"105","author":"Wachtel","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B106","doi-asserted-by":"crossref","first-page":"e0187398","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PLoS One"},{"key":"2024012320182548100_znad266-B107","first-page":"769","article-title":"The systems of metastatic potential prediction in pheochromocytoma and paraganglioma","volume":"10","author":"Wang","year":"2020","journal-title":"Am J Cancer Res"},{"key":"2024012320182548100_znad266-B108","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","article-title":"COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas","volume":"474","author":"Pierre","year":"2019","journal-title":"Virchows Arch"},{"key":"2024012320182548100_znad266-B109","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12020-021-02854-3","article-title":"Assessment of the AJCC staging system of pheochromocytomas\/paragangliomas","volume":"75","author":"Abdel-Rahman","year":"2022","journal-title":"Endocrine"},{"key":"2024012320182548100_znad266-B110","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"2024012320182548100_znad266-B111","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12022-020-09633-2","article-title":"Immunohistochemical staining for SOX10 and SDHB in SDH-deficient paragangliomas indicates that sustentacular cells are not neoplastic","volume":"31","author":"Powers","year":"2020","journal-title":"Endocr Pathol"},{"key":"2024012320182548100_znad266-B112","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/his.13277","article-title":"Succinate dehydrogenase (SDH)-deficient neoplasia","volume":"72","author":"Gill","year":"2018","journal-title":"Histopathology"},{"key":"2024012320182548100_znad266-B113","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1210\/jc.2018-02355","article-title":"Impact of 123I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma","volume":"104","author":"Rao","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B114","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12020-015-0544-7","article-title":"The incremental benefit of functional imaging in pheochromocytoma\/paraganglioma: a systematic review","volume":"50","author":"Brito","year":"2015","journal-title":"Endocrine"},{"key":"2024012320182548100_znad266-B115","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Taieb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024012320182548100_znad266-B116","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/RLU.0000000000004077","article-title":"Integrated PET\/MRI with 68Ga-DOTATATE and 18F-FDG in pheochromocytomas and paragangliomas: an initial study","volume":"47","author":"Xu","year":"2022","journal-title":"Clin Nucl Med"},{"key":"2024012320182548100_znad266-B117","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of 68Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis","volume":"60","author":"Han","year":"2019","journal-title":"J Nucl Med"},{"key":"2024012320182548100_znad266-B118","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1210\/clinem\/dgaa794","article-title":"Recurrence rate of sporadic pheochromocytomas after curative adrenalectomy: a systematic review and meta-analysis","volume":"106","author":"Holscher","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B119","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3390\/cancers15112890","article-title":"Long-term outcomes after surgery for pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Torresan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2024012320182548100_znad266-B120","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.33549\/physiolres.933719","article-title":"Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma","volume":"66","author":"B\u00edlek","year":"2017","journal-title":"Physiol Res"},{"key":"2024012320182548100_znad266-B121","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.eprac.2020.09.011","article-title":"Chromogranin A in a cohort of pheochromocytomas and paragangliomas: usefulness at diagnosis and as an early biomarker of recurrence","volume":"27","author":"Parisien-La Salle","year":"2021","journal-title":"Endocr Pract"},{"key":"2024012320182548100_znad266-B122","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/cancers11040586","article-title":"Chromogranin A in the laboratory diagnosis of pheochromocytoma and paraganglioma","volume":"11","author":"Bilek","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2024012320182548100_znad266-B123","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/eci.12245","article-title":"Clinical utility of chromogranin A in SDHx-related paragangliomas","volume":"44","author":"Zuber","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"2024012320182548100_znad266-B124","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1210\/jc.2019-00018","article-title":"The role of 68Ga-DOTA-octreotate PET\/CT in follow-up of SDH-associated pheochromocytoma and paraganglioma","volume":"104","author":"Kong","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B125","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.2967\/jnumed.120.259697","article-title":"Systemic radiopharmaceutical therapy of pheochromocytoma and paraganglioma","volume":"62","author":"Carrasquillo","year":"2021","journal-title":"J Nucl Med"},{"key":"2024012320182548100_znad266-B126","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12149-022-01798-6","article-title":"Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL)","volume":"37","author":"Takenaka","year":"2023","journal-title":"Ann Nucl Med"},{"key":"2024012320182548100_znad266-B127","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity Iodine-131 Metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2024012320182548100_znad266-B128","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024012320182548100_znad266-B129","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"key":"2024012320182548100_znad266-B130","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.118.230607","article-title":"NANETS\/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med"},{"key":"2024012320182548100_znad266-B131","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024012320182548100_znad266-B132","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1093\/oncolo\/oyab041","article-title":"Position statement on the diagnosis, treatment, and response evaluation to systemic therapies of advanced neuroendocrine tumors, with a special focus on radioligand therapy","volume":"27","author":"Capdevila","year":"2022","journal-title":"Oncologist"},{"key":"2024012320182548100_znad266-B133","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens"},{"key":"2024012320182548100_znad266-B134","first-page":"1667","article-title":"Efficacy and safety of tyrosine kinase inhibitors in patients with metastatic pheochromocytomas\/paragangliomas: a systematic review and meta-analysis","volume":"107","author":"Zhou","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2024012320182548100_znad266-B135","doi-asserted-by":"crossref","first-page":"1066208","DOI":"10.3389\/fendo.2022.1066208","article-title":"The use of temozolomide in paediatric metastatic phaeochromocytoma\/paraganglioma: a case report and literature review","volume":"13","author":"Urquhart","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024012320182548100_znad266-B136","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"2024012320182548100_znad266-B137","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/ERC-21-0392","article-title":"SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma","volume":"29","author":"Perez","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2024012320182548100_znad266-B138","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fendo.2020.00061","article-title":"Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma\/paraganglioma\u2014case report and review of the literature","volume":"11","author":"Tong","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024012320182548100_znad266-B139","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.3390\/cancers12082307","article-title":"Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas","volume":"12","author":"Jimenez","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2024012320182548100_znad266-B140","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fonc.2014.00166","article-title":"External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma","volume":"4","author":"Vogel","year":"2014","journal-title":"Front Oncol"},{"key":"2024012320182548100_znad266-B141","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","article-title":"External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma","volume":"3","author":"Breen","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"2024012320182548100_znad266-B142","first-page":"e4742","article-title":"Spine stereotactic radiosurgery for metastatic pheochromocytoma","volume":"11","author":"Mesko","year":"2019","journal-title":"Cureus"},{"key":"2024012320182548100_znad266-B143","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40618-022-01908-1","article-title":"Favorable outcome in advanced pheochromocytoma and paraganglioma after hypofractionated intensity modulated radiotherapy","volume":"46","author":"Gu","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"2024012320182548100_znad266-B144","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/cancers11020195","article-title":"Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma","volume":"11","author":"Kohlenberg","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2024012320182548100_znad266-B145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12871-018-0626-1","article-title":"Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series","volume":"18","author":"Deljou","year":"2018","journal-title":"BMC Anesthesiol"},{"key":"2024012320182548100_znad266-B146","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejvs.2018.10.038","article-title":"A systematic review and meta-analysis of the presentation and surgical management of patients with carotid body tumours","volume":"57","author":"Robertson","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2024012320182548100_znad266-B147","author":"Aspinal"},{"key":"2024012320182548100_znad266-B148","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2265.1997.d01-1751.x","article-title":"Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients","volume":"46","author":"Kasperlik-Zeluska","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024012320182548100_znad266-B149","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2214\/AJR.12.10302","article-title":"Morphologic features of 211 adrenal masses at initial contrast-enhanced CT: can we differentiate benign from malignant lesions using imaging features alone?","volume":"201","author":"Song","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"2024012320182548100_znad266-B150","doi-asserted-by":"crossref","first-page":"R51","DOI":"10.1530\/EJE-16-0461","article-title":"Management of endocrine disease: imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis","volume":"175","author":"Dinnes","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B151","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00259-010-1471-8","article-title":"18F-FDG PET\/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation","volume":"37","author":"Ansquer","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2024012320182548100_znad266-B152","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology clinical practice guideline in collaboration with the European Network for the Study of Adrenal Tumors","volume":"175","author":"Fassnacht","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B153","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/EJE-16-0297","article-title":"Diagnosis of endocrine disease: the diagnostic performance of adrenal biopsy: a systematic review and meta-analysis","volume":"175","author":"Bancos","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2024012320182548100_znad266-B154","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.surg.2013.06.021","article-title":"Adrenalectomy for solid tumor metastases: results of a multicenter European study","volume":"154","author":"Moreno","year":"2013","journal-title":"Surgery"},{"key":"2024012320182548100_znad266-B155","doi-asserted-by":"crossref","first-page":"zrac047","DOI":"10.1093\/bjsopen\/zrac047","article-title":"Outcome and prognosis after adrenal metastasectomy: nationwide study","volume":"6","author":"Vlk","year":"2022","journal-title":"BJS Open"},{"key":"2024012320182548100_znad266-B156","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00423-015-1293-z","article-title":"Surgical resection of metastases to the adrenal gland: a single center experience","volume":"400","author":"Hornstein","year":"2015","journal-title":"Langenbecks Arch Surg"},{"key":"2024012320182548100_znad266-B157","doi-asserted-by":"crossref","first-page":"350","DOI":"10.21037\/gs.2017.03.20","article-title":"The role of laparoscopic resection of metastases to adrenal glands","volume":"6","author":"Puccini","year":"2017","journal-title":"Gland Surg"},{"key":"2024012320182548100_znad266-B158","first-page":"29","article-title":"Adrenal metastases\u2014long-term results of surgical treatment, single-centre experience","volume":"24","author":"Samsel","year":"2020","journal-title":"Contemp Oncol (Pozn)"},{"key":"2024012320182548100_znad266-B159","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejso.2019.01.006","article-title":"Survival outcomes following adrenalectomy for isolated metastases to the adrenal gland","volume":"45","author":"Ramsingh","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2024012320182548100_znad266-B160","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/SLA.0000000000003876","article-title":"Adrenalectomy for secondary malignancy: patients, outcomes, and indications","volume":"274","author":"Wachtel","year":"2021","journal-title":"Ann Surg"},{"key":"2024012320182548100_znad266-B161","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/cancers14010156","article-title":"Outcomes after surgical treatment of metastatic disease in the adrenal gland; valuable for the patient?","volume":"14","author":"Metman","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024012320182548100_znad266-B162","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1245\/s10434-021-11192-7","article-title":"Survival after adrenalectomy for metastatic lung cancer","volume":"29","author":"Krumeich","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2024012320182548100_znad266-B163","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.radonc.2022.02.023","article-title":"Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period","volume":"170","author":"van Vliet","year":"2022","journal-title":"Radiother Oncol"},{"key":"2024012320182548100_znad266-B164","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/bjs\/znac315","article-title":"Adrenalectomy for metastases","volume":"109","author":"Zaborowski","year":"2022","journal-title":"Br J Surg"},{"key":"2024012320182548100_znad266-B165","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4274\/jus.galenos.2021.2020.0037","article-title":"Solitary metastasis of renal cell carcinoma to the adrenal gland: treatment outcomes following laparoscopic retroperitoneal adrenalectomy","volume":"8","author":"Parkin C","year":"2021","journal-title":"J Urol Surg"},{"key":"2024012320182548100_znad266-B166","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1097\/01.ju.0000125340.84492.a7","article-title":"Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy","volume":"171","author":"Siemer","year":"2004","journal-title":"J Urol"},{"key":"2024012320182548100_znad266-B167","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cllc.2017.03.002","article-title":"Ablative therapy for oligometastatic non-small cell lung cancer","volume":"18","author":"Juan","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"2024012320182548100_znad266-B168","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1096-9098(199809)69:1<54::AID-JSO11>3.0.CO;2-N","article-title":"Surgical management of adrenal metastases from lung cancer","volume":"69","author":"Beitler","year":"1998","journal-title":"J Surg Oncol"},{"key":"2024012320182548100_znad266-B169","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ejcts\/ezx193","article-title":"Exhaustive preoperative staging increases survival in resected adrenal oligometastatic non-small-cell lung cancer: a multicentre study","volume":"52","author":"De Wolf","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"2024012320182548100_znad266-B170","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0003-4975(00)02509-1","article-title":"Resection of adrenal metastases from non-small cell lung cancer: a multicenter study","volume":"71","author":"Porte","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"2024012320182548100_znad266-B171","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1200\/JCO.2007.14.2091","article-title":"Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis","volume":"26","author":"Tanvetyanon","year":"2008","journal-title":"J Clin Oncol"},{"key":"2024012320182548100_znad266-B172","first-page":"124","article-title":"Surgical treatment of adrenal metastasis following pulmonary resection for lung cancer: comparison of adrenalectomy with palliative therapy","volume":"79","author":"Higashiyama","year":"1994","journal-title":"Int Surg"},{"key":"2024012320182548100_znad266-B173","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.athoracsur.2011.05.116","article-title":"Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma","volume":"92","author":"Raz","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"2024012320182548100_znad266-B174","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/000313481508101019","article-title":"Adrenalectomy for metastatic melanoma: current role in the age of nonsurgical treatments","volume":"81","author":"Flaherty","year":"2015","journal-title":"Am Surg"},{"key":"2024012320182548100_znad266-B175","doi-asserted-by":"crossref","first-page":"53","DOI":"10.6004\/jnccn.2020.7800","article-title":"Melanoma metastases to the adrenal gland are highly resistant to immune checkpoint inhibitors","volume":"19","author":"Borgers","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2024012320182548100_znad266-B176","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.amjsurg.2019.11.033","article-title":"The non-responding adrenal metastasis in melanoma: the case for minimally invasive adrenalectomy in the age of modern therapies","volume":"220","author":"Zippel","year":"2020","journal-title":"Am J Surg"},{"key":"2024012320182548100_znad266-B177","doi-asserted-by":"crossref","first-page":"e26838","DOI":"10.1097\/MD.0000000000026838","article-title":"Bilateral adrenal metastasis of renal cell carcinoma 4 years after radical nephrectomy: a case report and review of literature","volume":"100","author":"Li","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2024012320182548100_znad266-B178","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/cen.14268","article-title":"Presentation, disease progression and outcomes of adrenal gland metastases","volume":"93","author":"Mao","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024012320182548100_znad266-B179","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijrobp.2008.10.079","article-title":"Stereotactic body radiotherapy for treatment of adrenal metastases","volume":"75","author":"Chawla","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024012320182548100_znad266-B180","doi-asserted-by":"crossref","DOI":"10.1177\/1533033818809983","article-title":"Real-time tumor-tracking radiotherapy and general stereotactic body radiotherapy for adrenal metastasis in patients with oligometastasis","volume":"17","author":"Katoh","year":"2018","journal-title":"Technol Cancer Res Treat"},{"key":"2024012320182548100_znad266-B181","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2020.01.017","article-title":"Stereotactic body radiation therapy of adrenal metastases: a pooled meta-analysis and systematic review of 39 studies with 1006 patients","volume":"107","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/111\/1\/znad266\/56343785\/znad266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/111\/1\/znad266\/56343785\/znad266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T20:20:09Z","timestamp":1706041209000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/doi\/10.1093\/bjs\/znad266\/7585615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":181,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,23]]},"published-print":{"date-parts":[[2024,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znad266","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2024,1]]},"article-number":"znad266"}}